Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · December 14, 2017

Benefit of Pioglitazone on CVD and Non-Alcoholic Steatohepatitis vs Low Risk of Bladder Cancer

Diabetes Research and Clinical Practice

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Research and Clinical Practice
An Updated Meta-Analysis of Pioglitazone Exposure and Bladder Cancer and Comparison to the Drug's Effect on Cardiovascular Disease and Non-Alcoholic Steatohepatitis
Diabetes Res. Clin. Pract. 2018 Jan 01;135(xx)102-110, MB Davidson, D Pan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading